HRT Financial’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

HRT Financial’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-19,935	Closed	-$743K	–	3971
2021 Q2	$743K	Buy	+19,935	New	+$611K	0.01%	1432
2021 Q1	–	Sell	-18,452	Closed	-$406K	–	3354
2020 Q4	$406K	Buy	+18,452	New	+$406K	0.01%	1132
2019 Q2	–	Sell	-13,549	Closed	-$198K	–	977
2019 Q1	$198K	Buy	+13,549	New	+$156K	0.03%	405

Other funds holding DRNA

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

HRT Financial's DRNA Position: Q3 2021 in Review

HRT Financial sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q3 2021, closing a stake of 19,935 shares — an estimated $743K sold.

HRT Financial first reported a position in DRNA in Q1 2019 and held it in 3 quarters. The position peaked at $743K in Q2 2021. 173 funds tracked by Wall St. Rank hold DRNA as of Q3 2021.

HRT Financial reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
HRT Financial sold 19,935 Dicerna Pharmaceuticals, Inc. shares in Q3 2021, an estimated $743K.
HRT Financial first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2019 and held it in 3 quarters.
HRT Financial's Dicerna Pharmaceuticals, Inc. position peaked at $743K in Q2 2021.
173 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q3 2021.

Based on HRT Financial's 13F filing for Q3 2021, filed 15 Nov 2021.